Priya Jayachandran, MD
Medical Oncology · Los Angeles, CANPI 1962768671
Payments from drug & device makers
Across 51 payments — averaging $3445.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$175K
- Amgen$49
- AstraZeneca$41
- Blueprint Medicines Corporation$30
- Puma Biotechnology, Inc.$29
- Bristol Myers Squibb$23
- plus $107 from 6 others
What the payments were for
- Food & beverage$279100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 38 | $175,434 |
| Amgen | 2 | $49 |
| AstraZeneca(2 entities) | 2 | $41 |
| Blueprint Medicines Corporation | 1 | $30 |
| Puma Biotechnology, Inc. | 1 | $29 |
| Bristol Myers Squibb | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Merck | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$175,713 in reported general payments places this provider in the 60th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 22 | $5,462 |
| Anastrozole | 94 | $1,350 |
| Tamoxifen Citrate | 43 | $737 |
| Letrozole | 19 | $523 |
| Diclofenac Sodium | 11 | $397 |
| Alendronate Sodium | 16 | $218 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Los Angeles
- Sarmad SadeghiLos Angeles$26.1M
- Heinz-Josef LenzLos Angeles$11.6M
- Anthony El-KhoueiryLos Angeles$10.5M
- Stephen LiuLos Angeles$8M
- Mark AgulnikLos Angeles$5M
- David QuinnLos Angeles$4M
- Daphne StewartLos Angeles$4M
- Patricia YoungLos Angeles$3.1M
- David TranLos Angeles$3.1M
- Syma IqbalLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.